FDA Warns AMRI Over Contamination At Mass. Plant
FDA representatives found particulate contamination in samples of AMRI's injection drugs and saw employees using potentially nonsterile gloves and garments at the company's Burlington, Mass. manufacturing facility, the agency said in an Aug. 17 letter.
These “significant violations” of manufacturing regulations for finished pharmaceuticals caused the products at issue to be “adulterated” under the Federal Food, Drug, and Cosmetic Act,...
To view the full article, register now.